Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study

BACKGROUND: Omalizumab is a fully humanized monoclonal antibody indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma. AIMS: The aim of this study was to evaluate social, healthcare expenditure and clinical outcomes changes after incorporating omali...

Descripción completa

Detalles Bibliográficos
Autores principales: Entrenas Costa, Luis Manuel, Casas-Maldonado, Francisco, Soto Campos, José Gregorio, Padilla-Galo, Alicia, Levy, Alberto, Álvarez Gutiérrez, Francisco Javier, Gómez-Bastero Fernández, Ana P., Morales-García, Concepción, Gallego Domínguez, Rocío, Villegas Sánchez, Gustavo, Mateos Caballero, Luis, Pereira-Vega, Antonio, García Polo, Cayo, Pérez Chica, Gerardo, Martín Villasclaras, Juan José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710309/
https://www.ncbi.nlm.nih.gov/pubmed/30684255
http://dx.doi.org/10.1007/s41669-019-0117-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710309/
https://www.ncbi.nlm.nih.gov/pubmed/30684255
http://dx.doi.org/10.1007/s41669-019-0117-4

Ejemplares similares